CH 4051

Drug Profile

CH 4051

Alternative Names: CH-4051; L-CH-1504

Latest Information Update: 27 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of South Alabama
  • Developer Lundbeck A/S
  • Class Anti-inflammatories
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Suspended Autoimmune disorders; Rheumatoid arthritis

Most Recent Events

  • 24 Jun 2014 Chelsea Therapeutics has been acquired and merged into Lundbeck A/S
  • 31 May 2012 Chelsea Therapeutics completes the phase II MOTION trial in Rheumatoid arthritis (treatment-resistant) in the US, Bulgaria and the Czech Republic (NCT01116141)
  • 31 May 2012 Suspended - Phase-I for Autoimmune disorders (in volunteers) in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top